Table 2: Clinical Trials Involving the Use of Jak Inhibitors

Agent Principal Targeted Jak(s) Indication Development Stage
Ruxolitinib Jak1, Jak2 Myelofibrosis FDA approved
Primary polycythemia Phase III trial
Primary thrombocythemia Phase II trial
Tofacitinib Jak3, Jak1 Rheumatoid arthritis FDA approval recommended
Psoriasis, IBD Phase II trial
Baricitinib Jak1, Jak2 Rheumatoid arthritis, Psoriasis Phase II trial
CYT387 Jak2 Myelofibrosis Phase II trial
GLPG-0634 Jak1 Rheumatoid arthritis Phase II trial
INCB18424 Jak1, Jak2 Psoriasis Phase II trial
Lestaurtinib Jak2 Myelofibrosis Phase II trial
Pacritinib Jak2 Myelofibrosis Phase II trial
VX-509 Jak3 Rheumatoid arthritis Phase II trial
R-348 Jak3 Rheumatoid arthritis Phase I trial

Back to Article